European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968, September 2005

Curcumin: The story so far

  • R.A. Sharma

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton SM2 5PT, UK. Tel.: +44 208 642 6011; fax: +44 208 661 3127.
  • ,
  • A.J. Gescher
  • ,
  • W.P. Steward

Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK

Received 15 March 2005; accepted 13 May 2005.

Abstract 

Curcumin is a polyphenol derived from the herbal remedy and dietary spice turmeric. It possesses diverse anti-inflammatory and anti-cancer properties following oral or topical administration. Apart from curcumin’s potent antioxidant capacity at neutral and acidic pH, its mechanisms of action include inhibition of several cell signalling pathways at multiple levels, effects on cellular enzymes such as cyclooxygenase and glutathione S-transferases, immuno-modulation and effects on angiogenesis and cell–cell adhesion. Curcumin’s ability to affect gene transcription and to induce apoptosis in preclinical models is likely to be of particular relevance to cancer chemoprevention and chemotherapy in patients. Although curcumin’s low systemic bioavailability following oral dosing may limit access of sufficient concentrations for pharmacological effect in certain tissues, the attainment of biologically active levels in the gastrointestinal tract has been demonstrated in animals and humans. Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.

Keywords: Carcinogenesis, Colorectal cancer, Chemoprevention

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)00477-6

doi:10.1016/j.ejca.2005.05.009

European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968, September 2005